One of the major complications of carotid artery stenting (CAS) is the development of a postprocedural ischemic stroke. [1] [2] [3] The manipulation of CAS guidewires and catheters over the stenotic carotid plaque may scrape off atherosclerotic material, thus resulting in a thromboembolic event. 2 Measures to reduce CAS-associated stroke rates would have important implications for patients.
An analysis of the material retrieved from cerebral protection devices following CAS demonstrated that the debris captured by filters has a different composition depending on the volume of the captured material. 4 The presence of fibrin and platelets, foam macrophages, cellular debris, amorphous material, and cholesterol crystals is associated with a larger volume of captured material. Fibrin and platelets comprise 64% of the particulate material when the volume of embolic material is >1 mm 3 but only 33.5% when the volume of embolic material is 1 mm. 3, 4 An analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke revealed a fibrin-rich distal portion and an erythrocyte-rich zone on the proximal part of the thrombi. 5 Due to blood stasis, additional postocclusion clots form in the distal end of the thromboembolic material that further increase the size of the thromboemboli. 5 The thromboemboli generated during CAS consist of a mixture of fibrin, platelets, atherosclerotic debris, and amorphous material from the carotid plaque. 4, 5 Thrombolysis using recombinant tissue plasminogen activator (rtPA) was approved for acute ischemic stroke in 1996 after the positive results of the National Institute of Neurological Disorders and Stroke (NINDS) 2 trial. 6 This was a randomized, double-blind trial of intravenously administered rtPA versus placebo in patients within 3 hours of the onset of an ischemic stroke. 6 Patients treated with rtPA were at least 30% more likely to have minimal or no disability at 3 months. 6 The probability of a good clinical outcome with rtPA decreases by >35% with each 30-minute delay (odds ratio [OR] ¼ 0.641; 95% confidence interval [CI] ¼ 0.423-0.922; adjusted P ¼ .01). 7 A pooled analysis of 8 trials showed that when using intravenous rtPA for the management of ischemic stroke, the odds of a favorable 3-month outcome increase as the time to rtPA treatment from stroke onset decreases (P ¼ .0269). 8 Adjusted ORs (95% CI) of a favorable 3-month outcome were 2.55 (1.44-4.52) for 0 to 90 minutes, 1.64 (1.12-2.40) for 91 to 180 minutes, and 1.34 (1.06-1.68) for 181 to 270 minutes in favor of the rtPA group, while there was no benefit beyond 4.5 hours. 8 These results clearly show that the faster rtPA treatment is initiated, the better the outcome.
Early treatment with rtPA is coupled with a higher chance of a good long-term outcome after ischemic stroke. 7, 8 Carotid artery stenting is performed under local anesthesia. If rtPA treatment was readily available and could be initiated as soon as possible when a patient has an ischemic stroke during CAS, this should improve CAS results. Thrombolysis would have no effect on the atherosclerotic debris and the amorphous material of the thromboemboli. However, rtPA would dissolve the thrombi and the postocclusion clots forming in the periphery of the thromboemboli and thus possibly limit the extent of the emboli. This should consequently reduce the severity of stroke and minimize the neurological symptoms.
One complication of intravenous thrombolysis using rtPA for ischemic stroke is intracerebral hemorrhage (ICH). In the NINDS trial, 9 symptomatic ICH occurred in 6.4% of the rtPA group and 0.6% of the placebo group (P < .001). Stroke severity as measured by the National Institutes of Health Stroke Scale Score (OR ¼ 1.8; 95% CI ¼ 1.2-2.9; P ¼ .003), and brain edema or mass effect on computed tomography before treatment (OR ¼ 7.8; 95% CI ¼ 2.2-27.1; P < .001) were independently associated with an increased risk of symptomatic ICH. 9 According to the current guidelines, 1 all patients with CAS should receive routine aspirin and statin treatment. A drawback of both agents is a possible increase in the occurrence of ICH and hemorrhagic strokes. There is evidence suggesting that aspirin treatment should not be considered a contraindication to thrombolysis. 10, 11 On the other hand, statins reduce thrombin generation and modify fibrinolytic balance by upregulating endogenous rtPA production and reducing expression of plasminogen activator inhibitor 1. 12, 13 This might lead not only to enhanced efficacy of rtPA but also to an increased risk of ICH.
The Heart Protection Study (HPS) 14 and the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) 15 study reported a higher incidence of hemorrhagic stroke in statin users versus nonusers. An analysis of the combined results of HPS and SPARCL on the effect of statin treatment on the occurrence of hemorrhagic strokes (n ¼ 8011 patients; 4008 statin users vs 4003 statin nonusers) concluded that statin use was associated with a 73% increase in the occurrence of hemorrhagic strokes (risk ratio ¼ 1.73; 95% CI ¼ 1.19-2.50; P ¼ .004). 16 The opposite opinion was supported in other reports. A systematic review and meta-analysis of 26 studies including >90 000 patients concluded that statin use does not increase the incidence of hemorrhagic strokes (0.32% vs 0.36%, for statin users vs nonusers, respectively; OR ¼ 0.90; 95% CI ¼ 0.65-1.22; P ¼ .15). 17 Similarly, a more recent systematic review and meta-analysis of 23 randomized trials and 19 observational studies was unable to discern an increase in the incidence of ICH with statins. 18 The effect of statin use on outcomes after thrombolysis for acute ischemic stroke is controversial. Some studies have demonstrated that prior statin use is associated with an increased frequency of ICH, [19] [20] [21] while others have failed to show an effect of statins on the occurrence of ICH. 22 A meta-analysis of 11 observational studies concluded that statin use was associated with an increased risk of developing ICH after thrombolytic therapy for ischemic stroke (OR ¼ 2.34; 95% CI ¼ 1.31-4.17; P ¼ .004). 23 An independent pooled observational study of 11 studies, however, failed to verify this conclusion. 24 In multivariable regression analysis, statin treatment was not associated with any ICH (OR ¼ 1.15; 95% CI ¼ 0.93-1.41) or symptomatic ICH (OR ¼ 1.32; 95% CI ¼ 0.94-1.85) in patients with stroke undergoing thrombolysis. 24 A recent opinion article supported that statin treatment should not be paused or abruptly discontinued either in patients with acute ischemic stroke receiving rtPA thrombolysis or in patients with acute ICH. 25 It was argued that the analyses of HPS and SPARCL linking statins to ICH were post hoc with a relatively low number of ICH events. 25 Discontinuation of statins after acute stroke means withholding a drug that improves the chance of good functional outcome. Statins improve endothelial function, increase blood flow, exert antiinflammatory and immunomodulatory effects, reduce coagulation and thrombosis, and show antioxidant properties. [26] [27] [28] [29] [30] [31] Taken together, available data do not indicate that statin treatment confers a substantially higher risk of ICH. In contrast, there is evidence that statin discontinuation leads to a rebound effect and an overshoot reversal of many beneficial pleiotropic effects. [32] [33] [34] Future studies should evaluate the effects of thrombolysis on the incidence and extent of postprocedural ischemic strokes associated with CAS procedures. The majority of CASassociated strokes occur during the procedure or in the first 30 days postprocedurally. 35 We hypothesize that a quick response service should be set up for patients with CAS having a stroke during the postprocedural period. Intra-arterial, catheter-directed thrombolysis using rtPA should be preferred over intravenous thrombolysis. 36 Intra-arterial thrombolysis has the theoretical advantage of achieving more complete recanalization with less fibrinolytic drug. Furthermore, clot lysis can be assessed with follow-up angiograms. 36 Drug infusion can be stopped when clot lysis is achieved, leading to potentially less thrombolytic drug being used. 36 Finally, with intraarterial thrombolysis, treatment has been initiated up to 6 hours after symptoms, thus expanding the time window. 36 If the stroke occurs or becomes apparent after the procedure is completed and the arterial access for CAS is out, reestablishing the intra-arterial access should be preferred over intravenous thrombolysis to minimize systemic bleeding complications (e.g., bleeding from the access site or ICH). A drawback of intra-arterial compared with intravenous thrombolysis is that it is more technically demanding and requires the catheter tip to be placed close to the clot.
In conclusion, immediate initiation of thrombolysis using rtPA may prove to be useful in reducing postprocedural ischemic stroke rates associated with CAS and thus improve outcomes of CAS.
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